ReviewClinical cancer research : an official journal of the American Association for Cancer Research2012
Using germline genomics to individualize pediatric cancer treatments.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma.Journal of neuro-oncology · 2021Article
- The Germline Variants rs61757955 and rs34988193 Are Predictive of Survival in Lower Grade Glioma Patients.Molecular cancer research : MCR · 2019Article
- Pharmacogenetic and pharmacogenomic discovery strategies.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs inFrontiers in pharmacology · 2018Article
- Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients.Clinical pharmacology and therapeutics · 2014Article
- Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era.Clinical pharmacology and therapeutics · 2014Review
- Design and implementation of a randomized controlled trial of genomic counseling for patients with chronic disease.Journal of personalized medicine · 2014Article
- Challenges and opportunities in childhood cancer drug development.Nature reviews. Cancer · 2012Review
- The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
- Epigenetic changes in pediatric solid tumors: promising new targets.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Review
- Genetically InFormed therapies--a "GIFT" for children with cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
- Promising therapeutic targets in neuroblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Review
- Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia.Frontiers in genetics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The amazing successes in cure rates for children with cancer over the last century have come in large part from identifying clinical, genetic, and molecular variables associated with response to therapy in large cooperative clinical trials and stratifying therapies according to the predicted risk of relapse. There is an expanding interest in identifying germline genomic variants, as opposed to genetic variants within the tumor, that are associated with susceptibility to toxicity and for risk of relapse. This review highlights the most important germline pharmacogenetic and pharmacogenomic studies in pediatric oncology. Incorporating germline genomics into risk-adapted therapies will likely lead to safer and more effective treatments for children with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.